Short‐Term, Low‐Dose Spironolactone for Treatment of Hyperandrogenic Symptoms of Polycystic Ovary Syndrome—A Systematic Review
Current evidence does not show any significant difference in the use of spironolactone when compared to metformin. Given its widespread use and limited safety concerns, spironolactone remains an off-label option, especially for those unable to take hormonal contraceptives. However, larger, better quality studies are needed to establish its efficacy in PCOS management.
Authors
- Yu‐Shui Ma (ORCID: https://orcid.org/0000-0002-5728-7458)
- Vikram Sinai Talaulikar (ORCID: https://orcid.org/0000-0002-2058-722X)
- Neha Deshpande
- Bassel Wattar
- Sophie Clarke (ORCID: https://orcid.org/0000-0002-5426-2941)
- Irene Karderinis
- Telma Martins Viveiros (ORCID: https://orcid.org/0009-0007-2367-2052)
Institutions
- University College Hospital (GB)
- Epsom and St Helier University Hospitals NHS Trust (GB)
- London Women's Clinic (GB)
- University College London (GB)
Publication Details
- Journal
- Clinical Endocrinology
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1111/cen.70062
- Primary Topic
- Ovarian function and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00